Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.

Gianluca TrifiròMarco MassariRoberto Da CasFrancesca Menniti IppolitoJanet SultanaSalvatore CrisafulliPaolo Giorgi RossiMassimiliano MarinoManuel ZorziEmanuela BovoOlivia LeoniMonica LudergnaniStefania Spila Alegianinull null

Published in: Drug safety (2020)

ACEI/ARB use is not associated with either an increased or decreased risk of all-cause mortality, compared with CCB use, in the largest cohort of hospitalised COVID-19 patients exposed to these drugs studied to date. The use of these drugs therefore does not affect the prognosis of COVID-19. This finding strengthens recommendations of international regulatory agencies about not withdrawing/switching ACEI/ARB treatments to modify COVID-19 prognosis.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
ejection fraction
end stage renal disease
newly diagnosed
angiotensin ii
angiotensin converting enzyme
prognostic factors
transcription factor
community acquired pneumonia